MedTrace Logo

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

NCT01409135 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-03-12

No results posted yet for this study

Summary

A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4.

Conditions

  • Tumors
  • Medical Oncology
  • Neoplasms

Interventions

DRUG

AGS-22M6E

IV Infusion

DRUG

ASG-22CE

IV Infusion

Sponsors & Collaborators

  • Agensys, Inc.

    collaborator INDUSTRY

  • Seagen Inc.

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Agensys, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-11
Primary Completion
2015-04-27
Completion
2015-04-27

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01409135 on ClinicalTrials.gov